勃起功能障碍药物与皮肤癌:美国退伍军人分析
该回顾性数据库研究利用美国退伍军人事务部信息计算基础设施数据库,比较接受磷酸二酯酶5抑制剂(PDE5i)治疗的退伍军人与非PDE5i使用者的皮肤癌发生情况。PDE5i使用者平均每年门诊就诊次数更多(8.9次,SD±9.50 vs 5.9次,SD±10.0;P<.0001)。作者认为存在混杂因素,PDE5i仍是勃起功能障碍的安全治疗。
要点
- PDE5i组恶性黑色素瘤比值比1.25(95%CI 1.22-1.28,P<.0001),基底细胞癌1.49(95%CI 1.46-1.51,P<.0001)。
- PDE5i使用者年均门诊就诊8.9次(SD±9.50),非使用者5.9次(SD±10.0),P<.0001。
- 作者认为混杂因素可能参与皮肤癌与PDE5i使用的关系,PDE5i仍是安全治疗。
核心结论
- 退伍军人使用PDE5i治疗勃起功能障碍者较非PDE5i使用者恶性黑色素瘤风险轻度增加、基底细胞癌风险增加更明显。
- PDE5i使用者门诊就诊率高于非使用者,作者认为混杂因素可能参与皮肤癌与PDE5i使用的关系。
- PDE5i药物仍是勃起功能障碍的安全治疗。
研究设计与样本
- 回顾性数据库审查,使用美国退伍军人事务部信息计算基础设施数据库。
- 检索19年期间接受PDE5i治疗勃起功能障碍的退伍军人,并选取非PDE5i退伍军人组进行对比分析。
- 测量两组随访时间、门诊就诊次数以及恶性黑色素瘤和基底细胞癌发生率。
主要发现
- PDE5i组平均年龄59.2岁(SD±10.8),非PDE5i组58.7岁(SD±10.8)。
- PDE5i组平均随访8.9年(SD±4.2),非PDE5i组8.5年(SD±4.3)。
- PDE5i组恶性黑色素瘤比值比1.25(95%CI 1.22-1.28,P<.0001),基底细胞癌比值比1.49(95%CI 1.46-1.51,P<.0001)。
- PDE5i使用者平均每年门诊就诊8.9次(SD±9.50),非PDE5i使用者5.9次(SD±10.0),P<.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the relationship between phosphodiesterase 5 inhibitor drugs (PDE5i) and skin cancers in a large-scale study of Veterans. METHODS: This was a retrospective database review using the Department of Veterans Affairs Informatics and Computing Infrastructure database. Veterans Affairs Informatics and Computing Infrastructure was searched 19 years for Veterans who received PDE5i treatment of erectile dysfunction. A non-PDE5i group of Veterans was selected for comparison analysis. Follow-up time, outpatient clinic visits and incidence of malignant melanoma (MM), and basal cell carcinoma (BCC) were measured in both groups. RESULTS: A total of 2.55 million Veterans were included in this study (1.27 million in each group). Mean age of the PDE5i group and non-PDE5i group was 59.2 years (standard deviation [SD] ± 10.8) and 58.7 (SD ± 10.8), respectively. Mean follow-up time for the PDE5i group was 8.9 years (SD ± 4.2) and 8.5 years (SD ± 4.3) for non-PDE5i group. Odds ratio for malignant melanoma and BCC in the PDE5i group was 1.25 (confidence interval 95%, 1.22-1.28, P <.0001) and 1.49 (confidence interval 95%, 1.46-1.51, P <.0001), respectively. PDE5i users showed more mean outpatient visits/year (8.9 SD ± 9.50) compared to non-PDE5i users (5.9 SD ± 10.0; P <.0001). CONCLUSION: Veterans prescribed PDE5is to treat erectile show a minimal increased risk of MM and a greater risk of BCC compared to non-PDE5i users. PDE5i users visited outpatient VA clinics at a higher rate than non-PDE5i users in this study. These findings suggest confounding variables are likely involved in the relationship between skin cancers and PDE5i use. PDE5i drugs remain a safe treatment for erectile dysfunction.
引用
- Christie A, Vera PL, Higgins M, et al. Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans. Urology. 2019. PMID: 30735744. doi:10.1016/j.urology.2019.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。